Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLDILOX: MEDI6570 in Patients With Prior Myocardial Infarction
jRCT2021200037Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis and myocardial infarction (MI) comparing MEDI6570 with Placebo (2 arms). Primary endpoint: Change in non-calcified plaque volume in the most diseased coronary segment. Started Jan 2021; status: active, not recruiting.
02
Drugs
golocdacimab
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on jRCT2021200037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200037.